Use of Cysteamine in the Treatment of Cystinosis

What this Trial Is About

Cystinosis is a rare inherited disease causing poor growth and kidney failure due to cystine buildup inside cells, which also affects organs like the thyroid, pancreas, eyes, and muscles. Researchers are observing patients with cystinosis treated with the drug cysteamine to monitor long-term effects, detect new complications, and support genetic studies of the disease. This observational study has contributed to understanding cystinosis over several decades and helped gain FDA approval for cysteamine treatment. Participants in this study have cystinosis and receive cysteamine, an oral medication that reduces cystine levels in white blood cells and tissues. Patients are admitted to the NIH Clinical Center about every two years for detailed testing over 1 to 3 days, which includes monitoring cystine depletion and assessing disease progression. The study maintains ongoing surveillance to understand the natural history and complications of cystinosis in treated patients. Throughout the study, participants undergo extensive evaluations during these periodic visits, including tests to track cystine levels and general health status. The research team uses this information to advise patients and the broader cystinosis community. Follow-up occurs every two years, providing long-term data on the condition and treatment effects. The total duration of participation can span multiple decades, reflecting the study’s commitment to long-term monitoring.

Use of Cysteamine in the Treatment of Cystinosis